A phase 1 study assessing AV-101, an inhaled, dry powder aerosol version of imatinib in health volunteers
Latest Information Update: 27 Nov 2022
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Aerovate Therapeutics
- 17 Nov 2022 Results presented in an Aerovate Therapeutics Media Release.
- 17 Nov 2022 According to an Aerovate Therapeutics Media Release, results from this study published in ERJ Open Research.
- 18 May 2021 Results published in an Aerovate Therapeutics Media Release.